Background Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a
potential alternative to allopurinol for patients with hyperuricemia and gout. Methods We …

Objective To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and
placebo in a large group of subjects with hyperuricemia and gout, including persons with …

OBJECTIVE: To determine whether the prevalence of gout and/or clinically significant
hyperuricemia increased in a managed care population over 10 years. METHODS: The study was …

Objective Gout affects ∼1–2% of the American population. Current options for treating
hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and …

To assess the safety, pharmacokinetics, and pharmacodynamics of febuxostat in subjects
with normal renal function or renal impairment, febuxostat (80 mg/d) was orally administered …

OBJECTIVE: Poor compliance with gout medications has been recognized, but seldom studied.
We investigated compliance with allopurinol among managed care enrollees suspected …

Background Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently
being developed for the management of hyperuricemia in patients with gout. Objective To …

OBJECTIVES: The goal of this analysis was to evaluate the impact of gout, a painful
inflammatory arthritis condition, on an employed population's health-related work absence and …

What is already known about this subject • Febuxostat is a novel nonpurine selective inhibitor
of xanthine oxidase. What this study adds • This is the first manuscript to address the effect …

Clinical benefit early in urate-lowering treatment of gout is difficult to document. We examined
data from 1,832 gouty subjects treated with either urate-lowering agents or placebo to …